Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023
DOI:
https://doi.org/10.33321/cdi.2025.49.028Keywords:
influenza, vaccine, GISRS, surveillance, laboratory, annual report, WHOAbstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record 15,014 human influenza-positive samples during 2023. Viruses were analysed for their antigenic, genetic, and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hens’ eggs for potential use in seasonal influenza virus vaccines. During 2023, influenza A(H1N1)pdm09 and influenza B/Victoria viruses predominated, accounting for 37% and 28% respectively of all viruses received, compared to 12% for influenza A(H3N2). The majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically and genetically similar to the respective WHO recommended vaccine strains for the southern hemisphere in 2023. Of 5,531 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, seven A(H1N1)pdm09 viruses showed highly reduced inhibition against oseltamivir.
Downloads
References
Hay AJ, McCauley JW. The WHO global influenza surveillance and response system (GISRS)—a future perspective. Influenza Other Respir Viruses. 2018;12(5):551–7. doi: https://doi.org/10.1111/irv.12565.
Monto AS. Reflections on the global influenza surveillance and response system (GISRS) at 65 years: an expanding framework for influenza detection, prevention and control. Influenza Other Respir Viruses. 2018;12(1):10–2. doi: https://doi.org/10.1111/irv.12511.
Australian Government Department of Health and Aged Care. National communicable disease surveillance dashboard. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 2024. [Accessed on 2 April 2024.] Available from: https://nindss.health.gov.au/pbi-dashboard/.
Sullivan SG, Carlson S, Cheng AC, Chilver MB, Dwyer DE, Irwin M et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Euro Surveill. 2020;25(47):2001847. doi: https://doi.org/10.2807/1560-7917.ES.2020.25.47.2001847.
Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction during the COVID-19 pandemic? Nat Rev Microbiol. 2021;19(12):741–2. doi: https://doi.org/10.1038/s41579-021-00642-4.
Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol. 2008;46(7):2189–94. doi: https://doi.org/10.1128/JCM.00398-08.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–77. doi: https://doi.org/10.1017/s0022172400022610.
Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol. 2010;84(13):6769–81. doi: https://doi.org/10.1128/JVI.00458-10.
Shu B, Kirby MK, Davis WG, Warnes C, Liddell J, Liu J et al. Multiplex real-time reverse transcription PCR for influenza A virus, influenza B virus, and severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2021;27(7):1821–30. doi: https://doi.org/10.3201/eid2707.210462.
Shu B, Wu KH, Emery S, Villanueva J, Johnson R, Guthrie E et al. Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol. 2011;49(7):2614–9. doi: https://doi.org/10.1128/JCM.02636-10.
Deng YM, Spirason N, Iannello P, Jelley L, Lau H, Barr IG. A simplified Sanger sequencing method for full genome sequencing of multiple subtypes of human influenza A viruses. J Clin Virol. 2015;68:43–8. doi: https://doi.org/10.1016/j.jcv.2015.04.019.
Zhou B, Deng YM, Barnes JR, Sessions OM, Chou TW, Wilson M et al. Multiplex reverse transcription-PCR for simultaneous surveillance of influenza A and B viruses. J Clin Microbiol. 2017;55(12):3492–501. doi: https://doi.org/10.1128/JCM.00957-17.
Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza A viruses. J Virol. 2009;83(19):10309–13. doi: https://doi.org/10.1128/JVI.01109-09.
Shepard SS, Meno S, Bahl J, Wilson MM, Barnes J, Neuhaus E. Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genomics. 2016;17(1):708. doi: https://doi.org/10.1186/s12864-016-3030-6.
Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121–3. doi: https://doi.org/10.1093/bioinformatics/bty407.
Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37(5):1530–4. doi: https://doi.org/10.1093/molbev/msaa015.
Yu G. Using ggtree to visualize data on tree-like structures. Curr Protoc Bioinformatics. 2020;69(1):e96. doi: https://doi.org/10.1002/cpbi.96.
Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res. 2016;132:178–85. doi: https://doi.org/10.1016/j.antiviral.2016.06.001.
World Health Organization (WHO) Global Influenza Programme. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitor (NAI). [Webpage.] Geneva: WHO; 2023. [Accessed on 29 March 2023.] Available from: https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza/neuraminidase-inhibitor.
Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21(16):1776–9. doi: https://doi.org/10.1016/s0264-410x(03)00071-9.
Stöhr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol Biol. 2012;865:147–62. doi: https://doi.org/10.1007/978-1-61779-621-0_9.
Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses. 2016;10(5):354–60. doi: https://doi.org/10.1111/irv.12383.
WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; I January 2011. Available from: https://www.who.int/publications/i/item/manual-for-the-laboratory-diagnosis-and-virological-surveillance-of-influenza.
Roth B, Mohr H, Enders M, Garten W, Gregersen JP. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine. 2012;30(3):517–22. doi: https://doi.org/10.1016/j.vaccine.2011.11.063.
Curran M, Hampson A. National influenza surveillance 1997. Commun Dis Intell. 1998;22(5):69–74.
Halliday L, Roberts L, Hampson A. Annual report of the National Influenza Surveillance Scheme, 1998. Commun Dis Intell. 1999;23(7):185–92.
Thomson J, Lin M, Hampson A. Annual report of the National Influenza Surveillance Scheme, 1999. Commun Dis Intell. 2000;24(6):145–52.
Firestone SM, Barr IG, Roche PW, Walker JC. Annual report of the National Influenza Surveillance Scheme, 2005. Commun Dis Intell Q Rep. 2006;30(2):189–200.
Li J, Hampson A, Roche PW, Yohannes K, Spencer JD. Annual report of the National Influenza Surveillance Scheme, 2004. Commun Dis Intell Q Rep. 2005;29(2):125–36.
Roche P, Spencer J, Hampson A. Annual report of the National Influenza Surveillance Scheme, 2001. Commun Dis Intell Q Rep. 2002;26(2):204–13.
Roche P, Spencer J, Merianos A, Hampson A. Annual report of the National Influenza Surveillance Scheme, 2000. Commun Dis Intell Q Rep. 2001;25(3):107–12.
Yohannes K, Roche P, Hampson A, Miller M, Spencer J. Annual report of the National Influenza Surveillance Scheme, 2003. Commun Dis Intell Q Rep. 2004;28(2):160–8.
Yohannes K, Roche P, Spencer J, Hampson A. Annual report of the National Influenza Surveillance Scheme, 2002. Commun Dis Intell Q Rep. 2003;27(2):162–72.
O’Brien K, Barr IG. Annual report of the National Influenza Surveillance Scheme, 2006. Commun Dis Intell Q Rep. 2007;31(2):167–79.
Owen R, Barr IG, Pengilley A, Liu C, Paterson B, Kaczmarek M et al. Annual report of the National Influenza Surveillance Scheme, 2007. Commun Dis Intell Q Rep. 2008;32(2):208–26.
Kaczmarek M, Owen R, Barr IG. Annual report of the National Influenza Surveillance Scheme, 2008. Commun Dis Intell Q Rep. 2010;34(1):8–22.
Pennington K, Owen R, Mun J. Annual report of the National Influenza Surveillance Scheme, 2009. Commun Dis Intell Q Rep. 2017;41(4):E383–454.
Gavin K, Owen R, Barr IG. Annual report of the National Influenza Surveillance Scheme, 2010. Commun Dis Intell Q Rep. 2017;41(4):E348–68.
Sullivan SG, Chow MK, Barr IG, Kelso A. Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2014. Commun Dis Intell Q Rep. 2015;39(4):E602–11.
Leung VK, Deng YM, Kaye M, Buettner I, Lau H, Leang SK et al. Annual report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2016. Commun Dis Intell (2018). 2019;43. doi: http://doi.org/10.33321/cdi.2019.43.3.
Leung VK, Spirason N, Lau H, Buettner I, Leang SK, Chow MK. Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015. Commun Dis Intell Q Rep. 2017;41(2):E150–60.
Peck H, Moselen J, Brown SK, Triantafilou M, Lau H, Grau M et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2019. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.43.
Roe M, Kaye M, Iannello P, Lau H, Buettner I, Tolosa MX et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.25.
Price OH, Spirason N, Rynehart C, Brown SK, Todd A, Peck H et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.16.
O’Neill G, Aziz A, Kuba M, Brown SK, Lau H, Soppe S et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020–2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.63.
Communicable Disease Epidemiology and Surveillance Section. Report of the National Influenza Surveillance Scheme, 2011 to 2018. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.12.
Diefenbach-Elstob TR, Chanthalavanh P, Bobbitt ME, Brown SK, Rynehart C, Spirason N et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.43.
WHO Global Influenza Programme. Influenza Update N° 384: 04 January 2021, based on data up to 20 December 2020. Geneva: WHO; 4 January 2021. Available from: https://cdn.who.int/media/docs/default-source/influenza/influenza-updates/2020/2021_01_04_surveillance_update_384.pdf.
Australian Government Department of Health and Aged Care. Australian Influenza Surveillance Report – 2023 End of Season Summary. Canberra: Australian Government Department of Health and Aged Care; December 2023. Available from: https://www.health.gov.au/sites/default/files/2023-12/aisr-2023-national-influenza-season-summary.pdf.
WHO. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. Geneva: WHO; 29 September 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season.
WHO. Recommended composition of influenza virus vaccines for use in the 2024–2025 northern hemisphere influenza season. Geneva: WHO; 23 February 2024. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season.
Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40. doi: https://doi.org/10.1001/jama.292.11.1333.
Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khvorov A, Valkenburg SA et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat Commun. 2022;13(1):1721. doi: https://doi.org/10.1038/s41467-022-29402-5.
Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022;27(39):2200753. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753.
Published
How to Cite
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
